Pharmacological characterisation of (E)-N-(3-iodoprop-2-enyl)-2β-carbomethoxy-3β-(4′-methylphenyl)nortropane (PE2I) binding to the rat neuronal dopamine transporter expressed in COS cells

被引:7
|
作者
Page, G [1 ]
Chalon, S
Emond, P
Maloteaux, JM
Hermans, E
机构
[1] Catholic Univ Louvain, Lab Pharmacol expt, FARL, B-1200 Brussels, Belgium
[2] Fac Med & Pharm, UPRESEA 1223, GEMCI, F-86005 Poitiers, France
[3] INSERM, Lab Biophys Med & Pharmaceut, F-38200 Tours, France
关键词
neuronal dopamine transporter; DA uptake; PE2I; GBR; 12935; COS cells; selective inhibitor;
D O I
10.1016/S0197-0186(01)00086-9
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The interaction of (E)-N-(3-iodoprop-2-enyl)-2beta-Carbomethoxy-3beta-(4'-methylphenyl) nortropane (PE2I) with the rat neuronal dopamine transporter (DAT) was studied in transfected COS cells by measuring its ability to inhibit DA uptake and by measuring its affinity in radioligand binding experiments. Saturable [H-3]DA uptake was measured in COS cells transiently transfected with the cDNA sequence encoding the rat DAT. Pharmacological characterisation of this uptake revealed functional properties with a V-max,a value of 45.05 +/- 2.62 pmol/mg protein per min and a K-m value of 2.86 +/- 0.28 muM. The specific [H-3]DA uptake was fully inhibited by 1 muM PE2I. Concentration response curves revealed the high potency of PE2I in inhibiting DA uptake (pEC(50) value of 8.70 +/- 0.33), 25 times higher than that observed for the reference DAT inhibitor, GBR 12935. On crude homogenates from transfected COS cells, PE2I displaced the specific binding of [3 H]GBR 12935 with a PKi value of 7.73 +/- 0.13. Accordingly, [I-125]PE2I was found to specifically recognise a single binding site population which is almost completely displaced by GBR 12935 and nomifensine. Saturation experiments revealed the high affinity of [I-125]PE2I (K-D value of 3.8 +/- 0.63 nM) that correlates with the high potency of PEN in inhibiting the [H-3]DA uptake. This contrasts with the results obtained with GBR 12935 for which a discrepancy was found between its high affinity in binding assays (KD value of 0.43 +/- 0.04 nM) and its rather low potency in functional assays (pEC50 value of 7.30 +/- 0.05). A relatively high level of [H-3]GBR 12935 binding was detected in non transfected COS cells. Such nomifensine resistant binding is attributed to the interaction of GBR 12935 with cytochrome P-450 as it was displaced by cis-(Z)-flupentixol (an inhibitor of cytochrome P-450). Such interaction was not observed using PE2I. Taken together, these data demonstrate that PE2I was a highly potent inhibitor of cloned DAT compared with GBR 12935 and provided a useful tool for further investigations in cells transfected with cDNA encoding the DAT. (C) 2001 Elsevier Science Ltd. All rights reserved.
引用
收藏
页码:105 / 113
页数:9
相关论文
共 46 条
  • [41] Synthesis and pharmacological activity of N-(2,2-dimethyl-3,4-dihydro-2H-1-benzopyran-4-yl)-4H-1,2,4-benzothiadiazine-3-carboxamides 1,1-dioxides on rat uterus, rat aorta and rat pancreatic β-cells
    Khelili, Smail
    Kihal, Nadjib
    Yekhlef, Mohamed
    de Tullio, Pascal
    Lebrun, Philippe
    Pirotte, Bernard
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2012, 54 : 873 - 878
  • [42] 4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A):: A potent and selective corticotrophin-releasing factor1 receptor antagonist.: I.: Biochemical and pharmacological characterization
    Gully, D
    Geslin, M
    Serva, L
    Fontaine, E
    Roger, P
    Lair, C
    Darre, V
    Marcy, C
    Rouby, PE
    Simiand, J
    Guitard, J
    Gout, G
    Steinberg, R
    Rodier, D
    Griebel, G
    Soubrie, P
    Pascal, M
    Pruss, R
    Scatton, B
    Maffrand, JP
    Le Fur, G
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2002, 301 (01): : 322 - 332
  • [43] Effect of the haloperidol tetrahydropyridine metabolite 4-(4-chlorophenyl)-1-[4-(4-fluorophenyl)-4-oxobutyl]-1,2,3,6-tetrahydropyridine on dopamine receptor and transporter binding - A nonhuman primate I-123-iodobenzamide and 2 beta-carbomethoxy-3 beta-(4-iodophenyl)tropane single photon emission computed tomographic study
    Oliver, DW
    Dormehl, IC
    VanderSchyf, CJ
    Neumeyer, JL
    Hugo, N
    Keeve, R
    Rossouw, NT
    MullerGartner, HW
    Castagnoli, N
    ARZNEIMITTEL-FORSCHUNG/DRUG RESEARCH, 1997, 47 (06): : 692 - 699
  • [44] EFFECTS OF THE MAJOR METABOLITE OF PHENCYCLIDINE, THE TRANS ISOMER OF 4-PHENYL-4-(1-PIPERIDINYL)CYCLOHEXANOL, ON [H-3] N-(1-[2-THIENYL]CYCLOHEXYL)-3,4-PIPERIDINE ([H-3]TCP) BINDING AND [H-3] DOPAMINE UPTAKE IN THE RAT-BRAIN
    BABA, A
    YAMAMOTO, T
    YAMAMOTO, H
    SUZUKI, T
    MOROJI, T
    NEUROSCIENCE LETTERS, 1994, 182 (01) : 119 - 121
  • [45] Striatal 123I-2β-carbomethoxy-3b-(4-iodophenyl)-N-(3-fluoropropyl)-nortropane single-photon emission computed tomography demonstrates nigral degeneration in the early stage of behavioural variant frontotemporal dementia: an autopsy case with frontotemporal lobar degeneration with trans-activation response DNA protein 43 type B
    Arafuka, Shusei
    Fujishiro, Hiroshige
    Iritani, Shuji
    Torii, Youta
    Miwa, Ayako
    Yabata, Hiroyuki
    Sekiguchi, Hirotaka
    Habuchi, Chikako
    Kawashima, Kunihiro
    Yoshida, Mari
    Iwasaki, Yasushi
    Ozaki, Norio
    PSYCHOGERIATRICS, 2022, 22 (04) : 580 - 585
  • [46] S33138[N-[4-[2-[(3aS, 9bR)-8-cyano-1,3a, 4,9b-tetrahydro[1]-benzopyrano[3,4-c] pyrrol-2(3H)-yl)-ethyl]phenylacetamide], a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent:: I.: Receptor-binding profile and functional actions at G-protein-coupled receptors
    Millan, Mark J.
    La Cour, Clotilde Mannoury
    Novi, Francesca
    Maggio, Roberto
    Audinot, Valerei
    Newman-Tancredi, Adrian
    Cussac, Didier
    Pasteau, Valerei
    Boutin, Jean-A.
    Dubuffet, Thierry
    Lavielle, Gilbert
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2008, 324 (02): : 587 - 599